272 related articles for article (PubMed ID: 31678767)
1. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
2. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
4. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
6. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
Oba K; Paoletti X; Alberts S; Bang YJ; Benedetti J; Bleiberg H; Catalano P; Lordick F; Michiels S; Morita S; Ohashi Y; Pignon JP; Rougier P; Sasako M; Sakamoto J; Sargent D; Shitara K; Cutsem EV; Buyse M; Burzykowski T;
J Natl Cancer Inst; 2013 Nov; 105(21):1600-7. PubMed ID: 24108812
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
Front Oncol; 2022; 12():835389. PubMed ID: 35463354
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
Eur J Cancer; 2013 Oct; 49(15):3149-58. PubMed ID: 23800671
[TBL] [Abstract][Full Text] [Related]
9. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
10. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
11. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
[TBL] [Abstract][Full Text] [Related]
12. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
16. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
Stahl M; Walz MK; Riera-Knorrenschild J; Stuschke M; Sandermann A; Bitzer M; Wilke H; Budach W
Eur J Cancer; 2017 Aug; 81():183-190. PubMed ID: 28628843
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis.
Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR
JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352
[TBL] [Abstract][Full Text] [Related]
20. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
